|
Characteristics
|
H1RA responders (n = 169)
|
H1RA non-responders (n = 113)
|
p value
|
|---|
|
Age (years)
|
42.3 ± 12.0
|
42.6 ± 11.4
|
0.665
|
|
Female n (%)
|
111 (65.7)
|
73 (64.6)
|
0.852
|
|
BMI (Kg/m2)
|
23.4 ± 4.1
|
23.6 ± 3.6
|
0.577
|
|
Urticaria duration (months)
|
28.8 ± 56.8
|
22.1 ± 43.0
|
0.289
|
|
UAS7 (0–42)
|
24.4 ± 10.3
|
28.8 ± 9.3
|
< 0.001
|
|
Log[Total IgE (kU/L)]
|
2.07 ± 0.5
|
2.13 ± 0.5
|
0.414
|
|
ECP (kU/L)
|
20.8 ± 16.5
|
23.1 ± 22.4
|
0.956
|
|
Total cholesterol (mg/dL)
|
194.8 ± 37.1
|
195.5 ± 36.3
|
0.985
|
|
Triglycerides (ng/dL)
|
148.7 ± 108.3
|
153.5 ± 84.8
|
0.288
|
|
LDL (mg/dL)
|
113.0 ± 37.8
|
110.7 ± 31.2
|
0.909
|
|
HDL (mg/dL)
|
56.1 ± 14.8
|
55.5 ± 15.3
|
0.862
|
|
Platelet (*1000/μL)
|
262.8 ± 56.7
|
263.0 ± 56.3
|
0.654
|
|
Mean platelet volume
|
8.0 ± 0.8
|
8.0 ± 0.7
|
0.544
|
|
Complement 3 (mg/dL)
|
108.6 ± 17.6
|
112.2 ± 24.7
|
0.525
|
|
Complement 4 (mg/dL)
|
26.3 ± 7.4
|
27.0 ± 8.6
|
0.481
|
|
H1RA dosea (mg/day)
|
21.0 ± 9.4
|
30.8 ± 13.3
|
< 0.001
|
|
Steroid use (%)
|
88 (52.1)
|
106 (93.8)
|
< 0.001
|
|
Cyclosporine use (%)
|
0
|
35 (31.0)
|
< 0.001
|
|
Omalizumab use (%)
|
0
|
38 (33.6)
|
< 0.001
|
|
PAF (pg/ml)
|
3804.6 [17.0–11716.4]
|
5426.4 [53.2–14768.3]
|
< 0.001
|
|
PAF-AH (ng/ml)
|
104.2 [2.6–296.5]
|
112.1 [4.4–256.9]
|
0.051
|
- p values were obtained by Pearson’s Chi square test for categorical variables and Mann–Whitney U-test for continuous variables
- Medication score, daily mean loratadine dose to control symptoms
- H1RA histamine receptor 1 antagonist, CSU chronic spontaneous urticaria, BMI body mass index, UAS7 sum of daily urticaria activity scores during the last week, ASST autologous serum skin test, ANA anti-nuclear antibody, ECP eosinophilic cationic protein, LDL low density lipoprotein, HDL high density lipoprotein, PAF platelet activating factor, PAF-AH platelet activating factor acetylhydrolase
- aH1RA dose is presented as the mean daily H1RA prescription calculated as the loratadine equivalent dose for 3 months
